Shopping Cart
Remove All
Your shopping cart is currently empty
Tregalizumab (Synonyms: BT-061, BT061)
Catalog No. T78291 Copy Product Info
Purity: 95%
🥰Excellent
Tregalizumab (BT-061) is a humanised monoclonal antibody targeting CD4, capable of binding unique epitopes on CD4 and selectively inducing regulatory T cell (Treg) activation. It holds potential applications in immunology and inflammation.
Tregalizumab
Copy Product Info🥰Excellent
Catalog No. T78291
Synonyms BT-061, BT061
Tregalizumab (BT-061) is a humanised monoclonal antibody targeting CD4, capable of binding unique epitopes on CD4 and selectively inducing regulatory T cell (Treg) activation. It holds potential applications in immunology and inflammation.
Tregalizumab
Cas No. 1207446-68-1
Customer service consultation
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $247 | - | In Stock | |
| 5 mg | $745 | - | In Stock | |
| 10 mg | $1,180 | - | In Stock | |
| 25 mg | $1,770 | - | In Stock | |
| 50 mg | $2,380 | - | In Stock |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:99.0% (SDS-PAGE); 98.3% (SEC-HPLC)
Appearance:Liquid
Color:Transparent
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Tregalizumab (BT-061) is a humanised monoclonal antibody targeting CD4, capable of binding unique epitopes on CD4 and selectively inducing regulatory T cell (Treg) activation. It holds potential applications in immunology and inflammation. |
| In vitro | Methods: Peripheral blood mononuclear cells (PBMCs) were treated with Tregalizumab (0-30 µg/mL for 18 hours), and the downregulation of CD4 expression was detected by flow cytometry. Results: At a concentration of 10 μg/mL Tregalizumab, CD4 expression in T cells significantly decreased and reached a steady state within 18 hours.[2] |
| Synonyms | BT-061, BT061 |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | CD4/LEU3 |
| Molecular Weight | 147.41 kDa |
| Cas No. | 1207446-68-1 |
| Isotype | Human IgG1 kappa |
| Recommended Isotype Control |
| Storage | Store at -20°C Shipping with blue ice/Shipping at ambient temperature. |
Citations
Calculator
Keywords
Preview
Related Tags: buy Tregalizumab | purchase Tregalizumab | Tregalizumab cost | order Tregalizumab | Tregalizumab in vitro | Tregalizumab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.